About the event
This event will bring scientific, government, and patient communities together to evaluate molecular targets and drug platforms for clear cell sarcoma and desmoplastic small round cell tumours, two ultra-rare cancers with high unmet needs.
Our involvement
At this event, one of our senior analysts, Joe Baxter, will deliver a presentation and a Q&A based on the outcomes of a desmoplastic small round cell tumour paediatric therapeutic development workshop from June 2025, which focused on target prioritisation for therapeutic development. Following this session, Joe will be participating in a 2 hour panel discussion.